ZURICH: Vaccines from AstraZeneca, Russia's Gamaleya Institute and Johnson & Johnson fight the coronavirus with another virus, leaving scientists concerned the shots may lose potency if annual inoculations become necessary to fight new variants. So-called viral vector shots - also used by several Chinese COVID-19 vaccine developers - use harmless modified viruses as vehicles, or vectors, to carry genetic information that helps the body build immunity against future infections. However, there is a risk that the body also develops immunity to the vector itself, recognising it as an intruder and trying to destroy it.
Most vector-vaccine developers have opted to use an adenovirus, a harmless class of common-cold viruses."The experience with adenoviruses has been for many years that vectors can be intercepted by the immune system after repeat injections," said Bodo Plachter, deputy director of the Institute of Virology at Mainz University's teaching hospital.
"There may be the same problem with other types of vectors. Only 'trial and error' will tell," he added.
That potentially puts vector vaccines at a disadvantage to mRNA shots from Pfizer and Moderna, or vaccines using deactivated coronaviruses, like Sinovac's, or the coronavirus' surface spike proteins, an approach pursued by Novavax. Vector immunity is not a new issue but has come under renewed scrutiny as companies including J&J anticipate regular COVID-19 vaccinations, like annual influenza shots, may be needed to combat new variants of the coronavirus.
Moderna as well as Pfizer and partner BioNTech said in separate statements this week they are studying additional booster shots that target new variants over time.
Even without any evolution in the virus, it is not yet clear whether vaccine-induced immune memory will eventually wane, which would also require booster shots. Scientists who spoke with Reuters acknowledged no definitive conclusions can be drawn about vector immunity's ultimate impact.
While it may prove surmountable in the end, health policymakers will still have to grapple with the question of which vaccines to deploy, and in what order, ahead of potential repeat inoculations.
A major validation of vector technology was the approval of Merck & Co's Ervebo inoculation against Ebola in 2019 and its use - and that of similar experimental vaccines - during outbreaks in Africa in prior years. But vector immunity has been implicated in past failures, including when a 2004 Merck AIDS vaccine trial flopped in men previously exposed to the adenovirus used for the vaccine. AstraZeneca declined to comment. J&J and the Russian Direct Investment Fund (RDIF), which is responsible for marketing the Sputnik vaccine made by the Gamaleya Institute abroad, did not respond to a request for comment.
MIX AND MATCH
One approach could be to combine different shots, known as "mixing and matching".
AstraZeneca and partner Oxford University's shot is being trialled with Russia's Sputnik V, and British scientists are testing Pfizer's mRNA shot with AstraZeneca's vaccine in a study funded by the British government, which says it is aware of the vector immunity issue.
The main motive for the British combination trial was to give healthcare providers flexibility in case of limited supplies, but Matthew Snape, the Oxford vaccinologist leading the project, said the question of vector immunity "is one of the reasons this study is interesting". He added there were plans to test for any anti-vector reaction by seeing how well a viral vector performs versus an alternative vaccine when given as a third dose.
Mainz University's Plachter is among those suggesting it may be more practical over the longer term to pivot to a class of vaccine that does not rely on vectors. "If after a while, you get to a standard immunization protocol, as with influenza, I would assume you would use other carriers," he said. AstraZeneca and the Gamaleya Institute have already sought to overcome vector immunity challenges under the standard COVID-19 two-shot regimen. The Russian lab employed two different viral vectors, seeking to prevent efficacy dropping from the primary dose to the booster shot, while AstraZeneca and Oxford use a chimpanzee virus vector to which humans would not previously have been exposed. But questions over a third or subsequent shot have yet to be addressed.
"One of the big sells for (AstraZeneca) was that there can be no existing immunity," Ian Jones, a professor of virology at Reading University, said. "This will not be the case once the world has had the COVID vaccines."
Since the vectors in the leading vaccines have been stripped of their ability to replicate, the antibody and T-cell responses they generate may, however, not be that strong. Moreover, only tiny vector volumes are needed for COVID-19 vaccines, in contrast with gene therapies where viral vectors serve as gene repair kits for diseased cells and vector immunity needs to be monitored closely because much larger quantities are injected. "The injected dose is so low that the induction of immunity to the capsid, or virus shell, remains low," said Luk Vandenberghe, a Harvard Medical School gene therapy expert working on a viral-vector COVID-19 vaccine.
Reuters
Fri Feb 26 2021
A healthcare worker administers a dose of the Sputnik V coronavirus disease (COVID-19) vaccine to her colleague in Podgorica, Montenegro. REUTERSpic
Pelajar tahfiz perlu teroka bidang teknologi
Kira-kira 200,000 pelajar tahfiz di negara ini, perlu dipastikan untuk mempunyai kemampuan dan peluang menjadi tenaga penggerak kepada umat Islam Malaysia dalam meneroka bidang yang dahulu dilihat sebagai asing., tegas Perdana Menteri Datuk Seri Anwar Ibrahim.
Perpaduan rakyat prasyarat ekonomi mampan
Tidak semua negara Islam mempunyai ruang dan kesempatan untuk terus aman dan damai, dan mempunyai peluang untuk menikmati ekonomi yang kukuh dan berkembang seperti Malaysia, tegas Perdana Menteri Datuk Seri Anwar Ibrahim.
Beliau berkata, rakyat Malaysia perlu mempunyai tekad untuk memahami maksud dan keperluan perpaduan di kalangan mereka, serta kekuatan dalaman yang seterusnya dapat dijadikan tonggak untuk negara membuat langkah seterusnya.
Beliau berkata, rakyat Malaysia perlu mempunyai tekad untuk memahami maksud dan keperluan perpaduan di kalangan mereka, serta kekuatan dalaman yang seterusnya dapat dijadikan tonggak untuk negara membuat langkah seterusnya.
Tidak perlu tergesa-gesa tukar ke lesen B - JPJ
Pemegang Lesen Memandu Malaysia (LMM) Kelas B2 dan B1 tidak perlu tergesa-gesa mendaftar Program Khas Peralihan LLM Kelas B2/B1 Kepada LMM Kelas B kerana tiada had masa ditetapkan untuk permohonan.
KPWKM teruskan lapan inisiatif bantu warga emas
Kementerian Pembangunan Wanita, Keluarga dan Masyarakat (KPWKM) akan terus menggerakkan lapan inisiatif utama dalam memenuhi keperluan jagaan dan sistem sokongan terhadap warga emas.
Warga emas maut ditikam anak kandung yang berhalusinasi
Seorang pesara guru maut ditikam anak kandungnya sendiri di sebuah rumah dekat Kampung Senaling, di sini, petang Sabtu.
Menurut Ketua Polis Daerah Kuala Pilah, Superintendan Amran Mohd Ghani, siasatan awal mendapati warga emas berusia 65 tahun itu cuba memujuk anak lelakinya yang juga pemegang kad orang kurang upaya (OKU) mental yang dikatakan mahu membunuh diri.
Menurut Ketua Polis Daerah Kuala Pilah, Superintendan Amran Mohd Ghani, siasatan awal mendapati warga emas berusia 65 tahun itu cuba memujuk anak lelakinya yang juga pemegang kad orang kurang upaya (OKU) mental yang dikatakan mahu membunuh diri.
Berita tempatan pilihan sepanjang hari ini
Berikut adalah berita yang paling menjadi tumpuan sepanjang Sabtu, 5 Oktober 2024.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah yang paling menjadi tumpuan sepanjang hari ini.
Hezbollah lancar serangan peluru berpandu ke atas kompleks industri ketenteraan di utara Israel
Pergerakan Hezbollah di Lubnan berkata mereka telah melancarkan serangan peluru berpandu ke atas kemudahan ATA Defence Industries.
Tiada kaitan dengan pelantikan CEO MDEC, Anuar Fariz bukan adik saya - Fahmi
Menteri Komunikasi Fahmi Fadzil menyangkal dakwaan Ketua Pegawai Eksekutif (CEO) baharu Perbadanan Ekonomi Digital Malaysia (MDEC) Anuar Fariz Fadzil merupakan adiknya.
Israel lakukan persiapan untuk serang Iran - Laporan
Tentera Israel sedang bersiap untuk "tindakan balas besar-besaran dan ekstrem" terhadap Iran.
‘Kes darah beku, serangan jantung tiada kaitan dengan vaksin AstraZeneca’
Golongan berisiko tinggi adalah individu yang mempunyai sejarah pembekuan darah dan mereka tidak dibenarkan menerima vaksin jenis AZ.
KKM keluar kenyataan berkaitan vaksin AstraZeneca dalam masa terdekat
KKM akan mengeluarkan kenyataan berhubung isu penarikan balik vaksin COVID-19 keluaran AstraZeneca dalam masa terdekat.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
AstraZeneca tarik balik vaksin COVID-19 di seluruh dunia, berbulan selepas sedar ada kesan sampingan
Vaksin itu tidak lagi boleh digunakan di EU selepas syarikat itu secara sukarela menarik balik "kebenaran pemasarannya."
KKM beri jaminan dedah data AEFI vaksin COVID-19 - Dr Dzulkefly
KKM memberi jaminan akan mendedahkan semua data berhubung kesan sampingan susulan imunisasi (AEFI) yang berpunca daripada vaksin COVID-19 pada satu waktu yang akan ditetapkan.
Tiada kesan sampingan daripada vaksin COVID-19 AstraZeneca di Indonesia - Suruhanjaya
Suruhanjaya Nasional untuk Kajian dan Pencegahan Peristiwa Mudarat Berikutan Imunisasi dan BPOM melakukan pemantauan bagi membuat rumusan.
Kesan sampingan vaksin: KKM akan dapatkan penjelasan AstraZeneca
Kementerian Kesihatan (KKM) akan mendapatkan penjelasan daripada firma farmaseutikal AstraZeneca berhubung kesan sampingan vaksin COVID-19 seperti yang dilaporkan media antarabangsa baru-baru ini.
AstraZeneca berjaya batalkan saman 12 individu berhubung isu suntikan vaksin COVID-19
Hakim Mahkamah Tinggi Dr Suzana Muhamad Said membenarkan permohonan Astrazeneca untuk membatalkan saman itu selepas mendengar hujahan kedua-dua pihak.
AstraZeneca rintis inisiatif kesaksamaan akses dalam perkhidmatan kesihatan
Portal mySihatPal menutup jurang akses kepada penyelesaian penjagaan kesihatan.
AstraZeneca tumpu kepada kepada penyakit jarang jumpa, teruskan pelaburan tempatan
AstraZeneca berhasrat menjadi pengupaya penyelesaian yang bekerjasama dalam aspek berbeza kepada pesakit.